Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma
ConclusionThis explorative study suggests that NAC can have a hepatoprotective activity in patients receiving trabectedin allowing to maintain an adequate dose intensity and continuative administration in patients with impaired liver and renal function or developing treatment-induced hepatotoxicity. A prospective randomized trial is warranted.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Acetylcysteine | Antidoxidants | Cancer | Cancer & Oncology | Liver | Sarcomas | Soft Tissue Sarcoma | Study | Toxicology | Urology & Nephrology